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2 
Abstract  35 
Obesity is undoubtedly caused by a chronic positive energy balance.  However, the early metabolic 36 
and hormonal responses to overeating are poorly described.  This study determined glycaemic 37 
control and selected gut hormone responses to nutrient intake before and after seven days of high-38 
fat overfeeding.  Nine healthy individuals (5 males, 4 females) performed a mixed meal tolerance 39 
test (MTT) before and after consuming a high-fat (65%) high-energy (+50%) diet for seven days.  40 
Measurements of plasma glucose, NEFA, acylated ghrelin, GLP-1, GIP and serum insulin were 41 
taken before (fasting) and at 30 minutes intervals throughout the 180 min MTT (postprandial).   42 
Body mass increased by 0.79 ± 0.14 kg after high-fat overfeeding (p < 0.0001), and BMI increased 43 
by 0.27 ± 0.05 kg/m2 (p = 0.002).  High-fat overfeeding also resulted in an 11.6% increase in 44 
postprandial glucose AUC (p = 0.007) and a 25.9% increase in postprandial insulin AUC (p = 45 
0.005).  Acylated ghrelin, GLP-1 and GIP responses to the MTT were all unaffected by the high-fat, 46 
high-energy diet.   These findings demonstrate that even brief periods of overeating are sufficient to 47 
disrupt glycaemic control.  However, as the postprandial orexigenic (ghrelin) and 48 
anorexigenic/insulintropic (GLP-1 and GIP) hormone responses were unaffected by the diet 49 
intervention, it appears that these hormones are resistant to short-term changes in energy balance, 50 
and that they do not play a role in the rapid reduction in glycaemic control.       51 
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3 
Introduction   68 
Changes in human behaviour, such as excessive food intake and/or insufficient physical activity, 69 
have made obesity a worldwide epidemic (1).  Furthermore, obesity is a significant risk factor for the 70 
development of insulin resistance and type II diabetes mellitus (T2DM).  However, despite the 71 
well-known association between obesity and T2DM, obesity may not trigger early metabolic 72 
dysfunction as changes in glycaemic control are often reported before substantial gains in body 73 
mass are observed.  For example, recent human studies report that even brief periods (5-14 days) of 74 
high-fat food intake can impair skeletal muscle insulin signalling (2), and reduce both hepatic (3) and 75 
whole-body insulin sensitivity (4,5).  In each of these studies the experimental diets provided an 76 
excess of energy as well as a high proportion of fat, and it is not yet clear if the observed 77 
impairments in glycaemic control are a result of the additional energy, the high fat content of the 78 
diets provided, or a combination of the two.  Likewise, the effect of overfeeding with mixed 79 
composition diets remains unknown.  However, an overconsumption of carbohydrate-rich foods (5 80 
days; +40% energy intake; 60% of energy from carbohydrate) has been reported to enhance skeletal 81 
muscle insulin signalling, evidenced by increased tyrosine phosphorylation of insulin receptor-1 82 
substrate (IRS-1) as well as increased IRS-1-associated phosphatidylinositol 3 (PI 3)-kinase 83 
activity, whereas high-fat overfeeding (5 days; +40% energy intake; 50% of energy from fat) in the 84 
same subjects was found to increase serine phosphorylation of IRS-1 and total expression of p85α 85 
(2).  Hence it would seem that a lipid overload explains the reduction in insulin sensitivity, rather 86 
than a positive energy balance alone.  This also fits with the hypothesis that it is an accumulation of 87 
reactive intra-myocellular lipid species, such as ceramide and diacylglycerol, that inhibits skeletal 88 
muscle insulin signalling and impairs GLUT4 translocation (6,7-8).     89 
 90 
Of the previous literature, there has been considerable interest in identifying the molecular 91 
mechanisms for peripheral (skeletal muscle) insulin resistance.  However, whole-body glycaemic 92 
control is coordinated by a variety of integrated physiological processes, involving multiple 93 
hormones and their target tissues, and the effects of high-fat food intake on these hormonal 94 
responses have received relatively little attention to date.  Of particular interest are the two primary 95 
incretin hormones: glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP).  96 
These two hormones are secreted from the intestines in response to nutrient ingestion and it is 97 
suggested that they act to control blood glucose levels by enhancing insulin secretion, suppressing 98 
glucagon release and slowing gastric emptying (9).  Patients with T2DM are known to have a 99 
diminished meal-induced secretion of GLP-1 (10,11).  Not only this, but they can also become 100 
resistant to the insulinotropic actions of GIP (12,13-14).  This loss of an incretin effect may be an 101 
important contributor to postprandial hyperglycaemia in T2DM (15).    Evidence for this also comes 102 
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from the effective use of GLP-1 receptor agonists and dipeptidyl peptidase (DPP)-IV inhibitors in 103 
the treatment of hyperglycaemia (16,17).   104 
 105 
Another gut hormone of interest is ghrelin, which is primarily secreted by the P/D1 cells lining the 106 
fundus of the stomach, and is thought to stimulate hunger via the orexigenic neuropeptide Y (NPY) 107 
and agouti-related peptide (AgRP) neurones of the hypothalamus (18).  Ghrelin levels are elevated 108 
during fasting and reduced following feeding (19), and ghrelin infusion has been shown to stimulate 109 
food intake in both animals (20) and humans (21) alike.  In healthy, normal weight individuals, ghrelin 110 
levels decrease in proportion to the energy content of the meal (22), whereas obese individuals 111 
exhibit both lower fasting levels (23,24-25) and reduced suppression following food intake (25,26).   112 
 113 
While the derangements in ghrelin and GLP-1 secretion have been reported in situations of chronic 114 
positive energy balance (i.e., obesity) and metabolic disease (i.e., insulin resistance), it is not yet 115 
clear whether the reported changes contribute to the development of obesity and insulin resistance, 116 
or are consequent of the disease state itself.  Therefore, the primary purpose of this study was to 117 
determine whether short-term, high-fat overfeeding, an experimental model which impairs whole-118 
body insulin sensitivity, influences gut hormone responses to fasting and feeding.  High-fat foods 119 
were chosen for the overfeeding intervention due to the frequent use of this model in both animal 120 
and human studies of metabolic disease.   121 
 122 
Materials and Methods  123 
Subjects  124 
Nine healthy individuals (5 males and 4 females; their physical characteristics can be seen in Table 125 
1) volunteered to participate in this study. The sample size was based on pilot data from our 126 
laboratory in which the effect size (Cohen’s d) of high-fat overfeeding on glycaemic control was 127 
calculated as 0.9 (i.e., a large effect).  Assuming a similar effect size in this study, α error 128 
probability of 0.05 and statistical power of 0.8, a sample size of at least 5 participants was required. 129 
The inclusion criteria required subjects to be physically active (exercising at least 3 times per week 130 
for more than 30 minutes at a time), non-smokers, free from cardiovascular and metabolic disease, 131 
not taking any medication, weight stable for at least 6 months, and with a normal body mass index 132 
(BMI: 18.5-24.9 kg/m2).  This study was conducted according to the guidelines laid down in the 133 
Declaration of Helsinki and approved by the Loughborough University Ethical Subcommittee for 134 
human participants. The experimental procedures and possible risks were fully explained to the 135 
subjects before their written informed consent was given. 136 
 137 
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Pre-testing  138 
Prior to the start of the study, subjects attended the laboratory for an initial assessment of their 139 
baseline anthropometric characteristics (height, weight and BMI). This information was then used 140 
to estimate their resting energy expenditure (REE) according to the calculations described by 141 
Mifflin et al., (27). A standard correction for physical activity level (1.6 and 1.7 times REE for 142 
females and males, respectively) was applied in order to estimate total daily energy requirements. 143 
This information was then used to determine individual energy intakes for the week-long 144 
overfeeding period (diet details described later).   145 
 146 
Experimental design 147 
After the initial pre-testing visit, subjects attended the laboratory for a mixed meal tolerance test 148 
(MTT) (details of which can be seen in the experimental protocol below). Subjects were then 149 
provided with all food to be consumed for the following 7 days.  The experimental diet was 150 
designed to be high in fat (65% total energy) and provide a severe energy excess (+50% kJ). All 151 
foods were purchased and prepared by the research team. Mean energy and macronutrient intake 152 
during the intervention period can be seen in Table 2 and a detailed example of typical daily food 153 
intake can be seen in Table 3.  Foods such as processed meats, dairy products, and pastries were 154 
used extensively throughout the diet intervention, and cooking instructions required subjects to fry 155 
foods where possible and to avoid wasting any fat left over from the cooking process. Saturated, 156 
monounsaturated and polyunsaturated fats made up 46 ± 0.9%, 37 ± 0.6%, and 9 ± 0.4% of the fat 157 
intake, respectively. Upon completion of the 7-day overfeeding period, subjects returned to the 158 
laboratory for a second MTT.    159 
 160 
Diet records, physical activity and compliance during high-fat overfeeding 161 
During the pre-testing visit, subjects were provided with standardised forms and digital kitchen 162 
scales for the purpose of recording weighed food intake for 3-5 day prior to the first main trial.  163 
Subjects also received detailed written and verbal instructions on how best to complete these 164 
records.  However, due to the well-known issues with self-reporting of energy intake (28), especially 165 
underreporting of food intake (29,30-31), even amongst lean and very well-motivated subjects (32), it 166 
was decided that estimated energy requirements would provide a better overall baseline from which 167 
to design and implement the overfeeding intervention.          168 
 169 
Subjects were expected to eat all of the food provided, and the importance of this was made 170 
explicitly clear to them during initial consultation and recruitment, but were told to report and 171 
return any uneaten foods so that our calculations could be adjusted if need be.  In order to improve 172 
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diet compliance, subjects were asked to complete a food preferences checklist to ensure that they 173 
only received foods that they were willing to eat; thereby increasing the palatability of the diet.  174 
Subjects were also given a copy of their diet plans and asked to tick off individual foods/meals as 175 
they were consumed.  Adherence to the diet was assessed by daily interviews that were conducted 176 
when subjects collected their food bundles.  Only one subject reported any issues with the diet, and 177 
they returned part of an uneaten steak and ale pie from one of the meals.  Other than this we are 178 
confident that the diet was followed; as evidenced by a consistent weight gain in all subjects.      179 
 180 
All subjects participated in physical activity on a regular basis and were required to continue this 181 
throughout the overfeeding period.  The written information and verbal instructions stated that 182 
subjects should expect to gain a small amount of weight and that they should not attempt to offset 183 
the additional energy intake by exercising longer, harder or more frequently.     184 
 185 
Experimental protocol  186 
On the experimental days (before and after overfeeding), subjects reported to the laboratory 187 
between 07.00 and 09.00 h after an overnight fast of at least 10 h. After voiding and being weighed, 188 
a 20 gauge Teflon catheter (Venflon, Becton, Dickinson, Plymouth, UK) was inserted into an 189 
antecubital vein of one arm to allow for repeated blood sampling during the 3 h MTT. A baseline, 190 
fasting blood sample (12.5 mL) was obtained before consumption of a standardized breakfast test 191 
meal (MTT). The MTT consisted of 45 g Rice Krispies, 72 g white bread (toasted), 20 g butter, 30 g 192 
strawberry jam and 300 mL whole milk. The energy intake and macronutrient composition of the 193 
test meal was 3227 kJ; 30 g fat, 112 g carbohydrate, and 19 g protein.  Upon finishing the meal, 194 
further blood samples of 12.5 mL were obtained at 30, 60, 90, 120, 150 and 180 min.   195 
 196 
Blood sampling  197 
For analysis of glucose, non-esterified fatty acids (NEFA), triglyceride, total cholesterol, HDL, 198 
LDL, GLP-1 and GIP, whole blood samples were collected in 4.9 mL ethylenediaminetetraacetic 199 
acid (EDTA; 1.75 mg/mL) treated tubes (Sarstedt, Leicester, UK) and spun at 1,750  g in  a 200 
refrigerated centrifuge (4°C) for 10 min. The resulting plasma was aliquoted into 1.5 mL 201 
Eppendorfs before being stored at -20°C until analysis. For analysis of insulin, whole blood was 202 
collected in 4.5 mL tubes containing a clotting catalyst (Sarstedt, Leicester, UK). Samples were left 203 
at room temperature until complete clotting had occurred; after which they were centrifuged at 204 
1,750 g for 10 min. The resulting serum was then aliquoted into 1.5 mL Eppendorfs and stored at -205 
20°C until analysis. Finally, to prevent the degradation of acylated ghrelin, a 25 µL solution 206 
containing potassium phosphate buffer (PBS), p-hydroxymercuribenzoic acid (PHMB) and sodium 207 
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hydroxide (NaOH) was mixed thoroughly with 2.5 mL of whole blood in 2.5 mL EDTA treated 208 
tubes. Samples were then centrifuged at 1,750 g for 10 min after which 500 µL of the resulting 209 
supernatant was removed and added to 50 µL of 1 M hydrochloric acid. Acidified samples were 210 
centrifuged for a further 5 min at 1,750 g before being stored at -20°C until analysis. 211 
 212 
Analytical procedures  213 
Plasma samples were analysed using commercially available spectrophotometric assays for glucose, 214 
triglyceride, HDL, LDL, total cholesterol (Horiba Medical, Northampton, UK) and NEFA (Randox, 215 
County Antrim, UK) concentrations using a semi-automatic analyzer (Pentra 400; Horiba Medical, 216 
Northampton, UK). The coefficient of variation (CV) for plasma glucose, triglyceride, HDL, LDL, 217 
total cholesterol and NEFA was 0.5, 3.0, 1.6, 0.5, 0.3 and 4.1%, respectively.  Serum insulin 218 
concentrations were determined using an enzyme-linked immuno-sorbent assay (ELISA: EIA-2935, 219 
DRG instruments GmBH, Germany) and the CV was 2%. Acylated ghrelin concentrations were 220 
determined using an ELISA (EIA-A05106, SPI BIO, France) and the CV was 16%. Total plasma 221 
GLP-1 and GIP concentrations were also determined via ELISA (EZGLP1T-36K and EZHGIP-222 
54K, respectively; Merck Millipore, Darmstadt, Germany). The CV was 7% for GLP-1 and 5% for 223 
GIP.  224 
 225 
Area under the curve (AUC)  226 
AUC for glucose and insulin was calculated using the trapezoidal rule with zero as the baseline.  227 
 228 
Statistics  229 
Data are presented as means ± standard error of the mean (SEM). Statistical analysis was performed 230 
using SPSS (V21.0) for windows (SPSS Inc, Chicago, IL). Fasting metabolic responses to high-fat 231 
overfeeding were compared using a paired t-test, whereas the dynamic hormonal and metabolic 232 
responses to the MTT were compared using a two-way (pre vs. post-overfeeding) repeated 233 
measures analysis of variance (ANOVA) and Bonferroni post hoc analysis where appropriate. 234 
Statistical significance was accepted where p < 0.05.  235 
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Results 237 
Weight gain and BMI  238 
All nine subjects gained body mass following 7 days of high-fat overfeeding (mean, 0.79 ± 0.14 kg; 239 
range, 0.30-1.3 kg; p < 0.0001, Table 1), and their BMI increased by 0.27 ± 0.05 kg/m2 (p = 0.002) 240 
(Table 1).   241 
 242 
Fasting plasma substrates 243 
Fasting substrate, hormone and lipoprotein concentrations before and after high-fat overfeeding are 244 
presented in table 4. Fasting plasma glucose, HDL cholesterol and GIP increased following 245 
overfeeding (p = 0.025, p = 0.012 and p = 0.017, respectively), while fasting plasma triglyceride 246 
and NEFA decreased (p = 0.039 and p = 0.023, respectively). Fasting serum insulin, plasma 247 
acylated ghrelin, total and LDL cholesterol, and GLP-1 were all unaffected by high-fat overfeeding.   248 
 249 
Mixed meal tolerance test 250 
Substrate and hormone responses to the 3 hour MTT are presented in figure 1. Plasma glucose and 251 
serum insulin concentrations increased in response to the MTT, peaking 30 min after meal 252 
ingestion.  Seven days of high-fat overfeeding increased plasma glucose AUC by 11.6% (from 1020 253 
± 74 mmol/L per 180 min to 1138 ± 56 mmol/L per 180 min; p = 0.007; figure 1a) and serum 254 
insulin AUC by 25.9% (from 53267 ± 6375 pmol/L per 180 min to 67046 ± 6849 pmol/L 180 min; 255 
p = 0.005; figure 1b) relative to baseline. Plasma NEFA concentrations decreased following food 256 
consumption. However, there was a more pronounced meal-induced suppression of plasma NEFA 257 
before high-fat overfeeding than afterwards (p < 0.0001; figure 1c).  Plasma acylated ghrelin 258 
concentrations decreased rapidly following food consumption (p < 0.0001; figure 1d), reaching a 259 
nadir at the 60 min sample point and remaining supressed throughout the entire postprandial 260 
measurement period.  This response was not influenced by high-fat overfeeding.  Plasma GLP-1 261 
concentrations peaked 30 min after food ingestion (p = 0.007), returning to fasting levels thereafter, 262 
with no difference before and after high-fat overfeeding (figure 1e).  Plasma GIP concentrations 263 
increased approximately 3-fold immediately following food consumption and remained elevated 264 
throughout the 3 h MTT (p < 0.0001), but again this response was not influenced by adherence to 265 
the high-fat, high-energy diet (figure 1f).     266 
 267 
Discussion  268 
The main finding of the present study was that postprandial responses of selected gut hormones 269 
(acylated ghrelin, GLP-1 and GIP) were unaffected by short-term, high-fat overfeeding, and that 270 
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only fasting levels of GIP were altered (increased) as a result of the dietary intervention.  A 271 
secondary finding was that excessive consumption of high-fat foods impaired glycaemic control, as 272 
evidenced by a significant increase in postprandial glucose and insulin AUC.   273 
 274 
The incretin hormones, GLP-1 and GIP, are thought to be responsible for the augmentation of 275 
insulin secretion that occurs after food intake compared with intravenous nutrient administration.    276 
We chose to investigate the impact of short-term, high-fat overfeeding on meal-induced GLP-1 and 277 
GIP responses as patients with T2DM exhibit a reduced GLP-1 secretion following nutrient 278 
ingestion (10,11)  and may become resistant to the insulinotropic actions of GIP (12,13-14), suggesting 279 
that a diminished incretin effect might be partly responsible for the development of postprandial 280 
hyperglycaemia.  In the present study, however, we report elevated postprandial glucose and insulin 281 
concentrations following 7 days of high-fat overfeeding without any changes in GLP-1 or GIP.  In 282 
this regard, elevated insulin concentrations are most probably a simple compensatory mechanism 283 
for reduced insulin sensitivity (hepatic and/or peripheral tissues) and elevated glucose 284 
concentrations.   Thus, an altered incretin effect does not appear to play a role in the early adaptive 285 
response to overnutrition or the observed impairment in glycaemic control.  Whilst we did observe 286 
a small, but significant, increase in fasting GIP concentrations, the physiological relevance of this 287 
remains unclear as fasting insulin concentrations were seemingly unaffected.   288 
 289 
As mentioned previously, ghrelin concentrations are known to increase during fasting and decrease 290 
following food intake (19).  This, combined with the observation that ghrelin administration 291 
stimulates appetite and food intake (20,21,33), has led to the suggestion that ghrelin is an appetite-292 
regulating hormone that is responsible (at least partially) for eating behaviour. Thus, reduced 293 
ghrelin levels reported in obese (23,24-25) and insulin resistant (34,35) individuals might represent a 294 
feedback loop by which the body attempts to reduce food intake within individuals that have been 295 
exposed to a chronic positive energy balance.  Ghrelin is also known to inhibit insulin secretion (36), 296 
and may, therefore, play a role in glucose homeostasis.  Indeed, ghrelin knock-out mice exhibit 297 
elevated basal insulin concentrations, enhanced glucose-stimulated insulin secretion, and improved 298 
peripheral insulin sensitivity when compared to wild-type mice (37).  With this in mind, reduced 299 
ghrelin levels might also be an attempt to lower glucose concentrations within hyperglycaemic 300 
obese and insulin resistant populations.  Given the discussion points above, we might have expected 301 
to see a high-fat diet-induced decrease in fasting and/or postprandial acylated ghrelin 302 
concentrations, especially as we observed significant gains in body mass (presumably body fat) and 303 
increases in both fasting and postprandial glucose concentrations, but this was clearly not the case 304 
(Figure 1D).   However, our results are in accordance with other overfeeding studies ranging in 305 
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duration from 3-100 days (3,38-40).  Thus it would seem that changes in circulating ghrelin 306 
concentrations occur secondary to the development of obesity and/or insulin resistance rather than 307 
in responses to relatively short-term positive energy balance or modest increases in blood glucose 308 
concentrations.    309 
 310 
Whilst the selected gut hormones demonstrated little response to the dietary intervention, high-fat 311 
overfeeding resulted in a significant increase in fasting glucose and postprandial glucose and insulin 312 
concentrations (Figures 1A and 1B), which is consistent with a number of previous human studies 313 
(4,5,41-43).  Others have reported impairments in skeletal muscle insulin signalling without (possibly 314 
before) a corresponding decrease in whole-body insulin sensitivity (2), or reduced hepatic insulin 315 
sensitivity without changes in peripheral glucose uptake (3).  The lack of mechanistic agreement 316 
between some of these studies is most likely explained by differences in the duration of 317 
overfeeding, the varying energy content and/or macronutrient composition of the diets 318 
administered, or the particular method used for assessing insulin action and glycaemic control (oral 319 
glucose tolerance test [OGTT] vs. hyperinsulinaemic euglycaemic clamp vs. mixed meal tolerance 320 
test [MTT]).  Where impairments in postprandial glycaemic control have been observed, it would 321 
be useful to know the processes responsible for such an effect.  Blood glucose concentrations are 322 
governed by the balance between the rate of appearance of glucose from the gut, endogenous 323 
glucose production (primarily from the liver), and peripheral glucose uptake (mainly skeletal 324 
muscle).  Therefore, the high-fat diet-induced increase in postprandial glucose concentration could 325 
be due to a defect in one, or a number, of these processes, which obviously warrants further 326 
investigation.           327 
 328 
In addition to changes in glucose and insulin concentrations, we also observed a significant 329 
decrease in fasting plasma triglyceride and NEFA concentrations after 7 days of high-fat 330 
overfeeding.  This is consistent with previous work by us (5) and others (2,44,45) and most likely 331 
reflects a decrease in endogenous triglyceride production as a result of increased fat consumption 332 
(46) and suppression of adipose tissue lipolysis as a result of consuming larger and/or more frequent 333 
meals.  It has been suggested that elevated NEFA concentrations might be responsible for the 334 
development of insulin resistance and T2DM (47).  This notion has been fuelled by classical reports 335 
of elevated NEFA concentrations in obesity (48) as well as acute studies in which NEFA have been 336 
elevated by means of intravenous lipid-heparin infusion (49).  The later approach elevates NEFA by 337 
activating lipoprotein lipase (LPL) located in the vascular endothelium and supplying a lipid-based 338 
substrate for hydrolysis.  More recently, however, the NEFA hypothesis of insulin resistance has 339 
been questioned as NEFA release per kilogram of adipose tissue is reduced as adipose tissue mass 340 
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increases, and lipid-heparin infusion trials often elicit NEFA concentration in excess of the disease 341 
state that they aim to mimic (50).  Whilst our data tend to support this change in consensus, in that 342 
we observed impaired glycaemic control at a time when fasting NEFA levels were reduced, we 343 
should also point out that frequent consumption of high-fat foods throughout the week-long diet 344 
intervention could have led to a considerable “spill-over” effect, whereby the hydrolysis of diet-345 
derived circulating triglycerides could have driven regular postprandial increases in plasma NEFA.   346 
 347 
It is also interesting to note that the high-fat-diet did not affect total or LDL cholesterol 348 
concentrations as one might have expected, whereas HDL cholesterol actually increased following 349 
the dietary intervention.  In general, saturated fats (that were highly prevalent in the present study) 350 
raise total and LDL cholesterol whereas polyunsaturated fats lower total and LDL cholesterol, and 351 
both types of fat increase HDL cholesterol (51,52).  It is likely that our study did not affect total or 352 
LDL cholesterol levels due to the short duration of the diet intervention.  Large scale population 353 
studies have demonstrated a strong association between low levels of HDL and cardiovascular 354 
disease risk (53,54-56); a risk that is progressively reduced with increasing levels of HDL (57).  This has 355 
been attributed to the potent anti-atherosclerotic properties of HDL (58).  However, it is important to 356 
note that the high-fat diet-induced increase in HDL may not represent an improvement in the 357 
plasma lipoprotein profile, as these diets have also been shown to reduce HDL particle uptake by 358 
the liver through a downregulation in the B1 scavenger receptors, which may explain the apparent 359 
rise in plasma concentrations (59).     360 
 361 
As a last point for consideration, our subjects were all healthy, young, lean and physically active, 362 
and yet they still exhibited a rapid reduction in glycaemic control as a result of excessive 363 
consumption of high-fat foods.  Whilst there is a paucity of information regarding the metabolic 364 
responses to overnutrition in humans, especially within at risk populations, one might expect even 365 
greater deleterious responses in those who are already overweight, sedentary or elderly.       366 
 367 
In conclusion, in this study we have provided further evidence that short-term, high-fat overfeeding 368 
leads to impairments in glycaemic control, as indicated by a significant increase in meal-induced 369 
glucose and insulin responses.  Furthermore, the postprandial responses of GLP-1, GIP and acylated 370 
ghrelin were not affected by the dietary intervention, suggesting that these selected gut hormones 371 
are not responsive to brief periods of positive energy balance and/or severe lipid overload.  372 
Therefore, the incretin hormones, and the gut peptide ghrelin, are not major regulators of the early 373 
adaptive responses to overnutrition.  374 
 375 
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18 
Table legends 581 
Table 1.  Values are mean ± SEM, n = 9. * Denotes significantly different to baseline, p < 0.05 582 
 583 
Table 2.  Values are mean ± SEM, n = 9. * Denotes significantly different to estimated energy 584 
requirement, p < 0.05. † Denotes significantly different to reported intake, p < 0.05 585 
 586 
Table 3.  Reported values are from a single subjects’ food intake on 1 day of the HFD intervention.  587 
Water intake was allowed ad libitum. 588 
 589 
Table 4.  Values are mean ± SEM, n = 9. * Denotes significantly different to before HFD, p < 0.05 590 
 591 
 592 
Figure legends 593 
Figure 1.  Plasma glucose (A), serum insulin (B), plasma NEFA (C), acylated ghrelin (D), total 594 
GLP-1 (E), and total GIP (F) concentrations during a 3 hour meal tolerance test conducted before 595 
and after 7-days of high-fat overfeeding. Values presented are mean ± SEM (n = 9). # Denotes 596 
significant main effect of trial/HFD diet (p < 0.05). * Denotes significant difference between trials 597 
at the annotated time point (p < 0.05).         598 
 599 
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Table 1.  Subject characteristics before and after 7 days of high-fat overfeeding 616 
Characteristics Baseline 7-days overfeeding 
Age (years) 23 ± 1 - 
Height (cm) 171.6 ± 2.0 - 
Body mass (kg) 65.6 ± 2.1 66.3 ± 2.0 * 
BMI (kg/m2) 22.3 ± 0.6 22.5 ± 0.6 * 
 617 
 618 
Table 2.  Estimated daily energy requirement and actual energy and macronutrient intake during the 619 
high-fat overfeeding period  620 
 Estimated energy 
requirement 
Self-reported 
habitual intake 
Experimental 
energy intake 
Energy (kJ) 10717 ± 481 8593 ± 749 16075 ± 722 *† 
Fat (g) - 74 ± 10 277 ± 12 † 
Carbohydrate (g) - 263 ± 23 211 ± 9 † 
Protein (g) - 100 ± 12 125 ± 6 † 
 621 
 622 
Table 3. Example food intake for 1 day of high-fat overfeeding  623 
Breakfast 
Foods 3 large pork sausages (175 g), 4 rashers of streaky bacon (80 g), 
2 large fried eggs (120 g), 1 medium slice of fried white bread 
(36 g), whole milk (300 mL) 
Protein (g) 61 
Carbohydrate (g) 47 
Fat (g) 93 
Energy (kJ) 5277 
20 
% of the days intake 31 
Lunch 
Foods 2 slices of medium white bread (72 g), butter (15 g), cheddar 
cheese (70 g), mayonnaise (15 g) 
Protein (g) 27 
Carbohydrate (g) 36 
Fat (g) 47 
Energy (kJ) 2810 
% of the days intake 16 
Snack 
Foods Potato crisps (50 g), milk chocolate bar (49 g) 
Protein (g) 7 
Carbohydrate (g) 55 
Fat (g) 32 
Energy (kJ) 2238 
% of the days intake 13 
Dinner 
Foods 2 beef burgers (200 g), 4 rashers of streaky bacon (80 g), 
cheddar cheese (60 g), coleslaw (100 g) 
Protein (g) 63 
Carbohydrate (g) 5 
Fat (g) 115 
Energy (kJ) 5411 
% of the days intake 31 
21 
Dessert 
Foods Chocolate sundae (140 g) 
Protein (g) 4 
Carbohydrate (g) 37 
Fat (g) 21 
Energy (kJ) 1474 
% of the days intake 9 
Total intake 
Protein (g) 162 
Carbohydrate (g) 180 
Fat (g) 308 
Energy (kJ) 17210 
 624 
 625 
Table 4. Fasting plasma substrate and hormone concentrations before and after 7-days of high-fat 626 
overfeeding 627 
 Before HFD After HFD 
Glucose (mmol/L) 5.5 ± 0.1 5.8 ± 0.1 * 
Insulin (pmol/L) 67 ± 8 79 ± 9 
NEFA (mmol/L) 0.60 ± 0.05 0.40 ± 0.06 * 
Triglyceride (mmol/L) 1.0 ± 0.1 0.7 ± 0.1 * 
Total cholesterol (mmol/L) 4.0 ± 0.2 4.0 ± 0.2 
HDL (mmol/L) 1.3 ± 0.1 1.5 ± 0.1 * 
LDL (mmol/L) 1.8 ± 0.2 1.8 ± 0.1 
Acylated ghrelin (pmol/L) 318 ± 57 268 ± 39 
GLP-1 (pmol/L) 31 ± 4 31 ± 4 
GIP (pmol/L) 22 ± 2 36 ± 6 * 
 628 
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 629 
